Soligenix News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.10.24	Soligenix, Sterling Pharma Partner To Develop Production Technology For Synthetic Hypericin (RTTNews)
25.06.24	Soligenix Rises In Pre-Market On Positive Results From Study Of HyBryte Vs. Valchlor In CTCL (RTTNews)
25.06.24	Soligenix Reports Positive Results From Study Of HyBryte Vs. Valchlor In Cutaneous T-cell Lymphoma (RTTNews)
31.05.24	Soligenix Announces 1-for-16 Reverse Stock Split (RTTNews)
11.04.24	Soligenix's SuVax Granted FDA Orphan Drug Designation For Prevention Of Sudan Ebolavirus Infection (RTTNews)
04.01.24	Soligenix Reports Positive Preliminary Results From Phase 2a Study Of SGX302 In Psoriasis (RTTNews)
02.01.24	Soligenix Reports Preclinical Efficacy Of Bivalent Vaccine Against Two Viruses (RTTNews)
02.01.24	Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses (PR Newswire)
01.12.23	"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery (PR Newswire)
30.11.23	FDA Clears Phase 2a Study Of SGX945 To Treat Aphthous Ulcers In Behcet's Disease (RTTNews)
30.11.23	Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease (PR Newswire)
17.11.23	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire)
13.11.23	Soligenix Q3 Loss Narrows (RTTNews)
13.11.23	Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results (PR Newswire)
20.10.23	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire)
16.10.23	Soligenix to Present at The ThinkEquity Conference (PR Newswire)
25.09.23	Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures (PR Newswire)
22.09.23	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders (PR Newswire)
21.08.23	Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial Results (PR Newswire)
10.08.23	HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment (PR Newswire)
11.07.23	Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis (PR Newswire)
16.05.23	Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis (PR Newswire)
15.05.23	Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial Results (PR Newswire)
11.05.23	Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
09.05.23	Soligenix Announces Closing of $8.5 Million Public Offering (PR Newswire)
05.05.23	Soligenix Announces Pricing of $8.5 Million Public Offering (PR Newswire)
04.05.23	Soligenix Announces Positive Results From Study Of HyBryte In CTCL Treatment; Stock Surges (RTTNews)
04.05.23	Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
01.05.23	Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease (PR Newswire)
24.04.23	Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
14.04.23	Soligenix Provides Regulatory Update on HyBryte™ (PR Newswire)
05.04.23	Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302 (PR Newswire)
03.04.23	Soligenix Says FDA Grants Type A Meeting Regarding New Drug Application For HyBryte (RTTNews)
03.04.23	Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
31.03.23	Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results (PR Newswire)
09.03.23	Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
14.02.23	Soligenix Receives Refusal To File Letter From FDA For HyBryte NDA (RTTNews)
14.02.23	Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
09.02.23	Soligenix Announces Reverse Stock Split (PR Newswire)
19.01.23	Soligenix Invited to Present at the Virtual Investor Summit Event (PR Newswire)
23.12.22	Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock (PR Newswire)
20.12.22	Soligenix: Positive Correlates Of Protection With RiVax In NHP Survival After Ricin Challenge (RTTNews)
20.12.22	Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge (PR Newswire)
19.12.22	Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis (PR Newswire)
15.12.22	Soligenix Submits NDA For HyBryte (RTTNews)
15.12.22	Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma (PR Newswire)
15.11.22	Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program (PR Newswire)
10.11.22	Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results (PR Newswire)
27.10.22	Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses (PR Newswire)
25.10.22	Soligenix Announces Formation of Psoriasis Medical Advisory Board (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	512.60	3.62 %	K V
Logitech Intl	80.90	2.17 %	K V
UBS Group	30.00	2.11 %	K V
Sika	222.20	1.55 %	K V
Sonova Hldg	304.50	1.36 %	K V
Novartis	90.53	0.47 %	K V
Roche Hldg G	264.60	0.46 %	K V
Alcon	75.96	0.34 %	K V
CieFinRichemont	139.85	-0.25 %	K V
Nestle	73.60	-0.76 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Soligenix Inc Registered Shs (Old)

Aktien Top/Flop

Meistgelesene Nachrichten